CRISPR Therapeutics AG and Vertex Pharmaceuticals received FDA approval for a CRISPR-based gene-editing therapy for sickle cell disease, with a wholesale acquisition cost of $2.2 million and a $200 million milestone payment from Vertex to CRISPR Therapeutics.